Kelyniam Engages Pharmexsys to Support Commercial Launch
April 27 2011 - 4:00PM
Marketwired
Kelyniam Global, Inc. (PINKSHEETS: KLYG), an emerging medical
device company, announced today that it has engaged Pharmexsys, LLC
to support the launch of their recently approved patient specific
custom cranial implant. Pharmexsys is a consulting firm that
specializes in helping early stage life science companies design
and develop the business systems and infrastructure required to
manage rapid growth.
"We selected Pharmexsys because of their focus on the life
science space and the breadth of their experience across many
operational functions within a business," said James Ketner,
President and CEO of Kelyniam Global. "Engaging Pharmexsys will
accelerate the launch of our first product and ensure that our
internal systems are robust and able to manage the strong demand
for the product."
The Kelyniam Custom Skull Implants (CSI) are designed and
manufactured for each individual patient to correct or replace bony
voids in the cranial skeleton caused by trauma or birth defects.
The company received FDA clearance to market their custom cranial
implant made from PEEK-OPTIMA® earlier this month. Streamlined
CAD/CAM design and manufacturing techniques will enable Kelyniam to
deliver patient specific implants within 24 hours of receiving an
order.
"I am pleased to be working with an innovative and customer
focused company like Kelyniam," said Ross Bjella, Pharmexsys'
President. "Our experience working with rapidly growing life
science companies makes Pharmexsys uniquely capable of designing
the infrastructure and implementing the business processes required
to meet Kelyniam's demanding needs."
Kelyniam is planning to launch the CSI product through
independent sales representatives early third quarter this
year.
About Pharmexsys, LLC:
Pharmexsys, LLC is a consulting firm focused on the unique needs
of small and mid-tier life science and B2B healthcare service
companies. Founder Ross Bjella is a proven life science executive
with deep experience in management, B2B business services, strategy
development, product and corporate branding and positioning, new
product launches, 3PL selection, supply chain efficiency and
contract negotiations. In 2009, PharmaVoice magazine named Ross one
of the Top 100 Most Inspiring People in Pharmaceuticals. Ross is an
advisor to the Wisconsin Early Stage Fund and has advised multiple
early stage companies and was a two time regional finalist in Ernst
& Young's Entrepreneur of the Year program. To learn more, go
to www.pharmexsys.com.
About Kelyniam Global, Incorporated:
Kelyniam Global, Inc. specializes in the use of CAD/CAM
technology to provide patient specific custom implants to assist
medical professionals by allowing them to operate more effectively,
improve patient care, and reduce health care costs by providing the
highest quality products available with today's technology. The
company is continually researching and developing new products and
processes to help patients live more active and productive lives.
Please visit our website at www.kelyniam.com for more
information.
Forward-Looking Statements Except for
historical information contained in this release, the matters
discussed are forward-looking statements that involve risks and
uncertainties. When used in this release, words such as
"anticipate," "believes," "estimate," "expect," "should," "intend,"
"projects," "objective" and "appears" and similar expressions, as
they relate to the Company or its management, identify
forward-looking statements. Such forward-looking statements are
based on the beliefs of the Company's management, as well as
assumptions made by and information currently available to the
Company's management. Among the factors that could cause actual
results to differ materially are the following: the effect of
business and economic conditions; the impact of competitive
products and pricing; capacity and supply constraints or
difficulties; product development, commercialization or
technological difficulties; the regulatory and trade environment;
the impact of reimbursement rates and coverage; and the risk
factors reported from time to time in the Company's SEC reports.
The Company undertakes no obligation to revise any forward-looking
statements as a result of future events or developments.
Contact: Kelyniam Global, Inc. www.kelyniam.com 1-800-280-8192
Email Contact
Kelyniam Global (PK) (USOTC:KLYG)
Historical Stock Chart
From May 2024 to Jun 2024
Kelyniam Global (PK) (USOTC:KLYG)
Historical Stock Chart
From Jun 2023 to Jun 2024